{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T18:35:58Z","timestamp":1771007758265,"version":"3.50.1"},"reference-count":65,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>BCR::ABL1-negative myeloproliferative neoplasms (MPNs) include three major subgroups\u2014polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF)\u2014which are characterized by aberrant hematopoietic proliferation with an increased risk of leukemic transformation. Besides the driver mutations, which are JAK2, CALR, and MPL, more than twenty additional mutations have been identified through the use of next-generation sequencing (NGS), which can be involved with pathways that regulate epigenetic modifications, RNA splicing, or DNA repair. The aim of this short review is to highlight the impact of molecular biology on the diagnosis, prognosis, and therapeutic management of patients with PV, ET, and PMF.<\/jats:p>","DOI":"10.3390\/cells12010105","type":"journal-article","created":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T02:50:01Z","timestamp":1672109401000},"page":"105","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of Molecular Biology in Diagnosis, Prognosis, and Therapeutic Management of BCR::ABL1-Negative Myeloproliferative Neoplasm"],"prefix":"10.3390","volume":"12","author":[{"given":"Norman","family":"Abbou","sequence":"first","affiliation":[{"name":"Molecular Biology Laboratory, North University Hospital, 13015 Marseille, France"},{"name":"INSERM, INRAE, C2VN, Aix-Marseille University, 13005 Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Piazzola","sequence":"additional","affiliation":[{"name":"Hematology and Cellular Therapy Department, Conception University Hospital, 13005 Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Gabert","sequence":"additional","affiliation":[{"name":"Molecular Biology Laboratory, North University Hospital, 13015 Marseille, France"},{"name":"INSERM, INRAE, C2VN, Aix-Marseille University, 13005 Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Ernest","sequence":"additional","affiliation":[{"name":"Hematology Laboratory, Timone University Hospital, 13005 Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Arcani","sequence":"additional","affiliation":[{"name":"INSERM, INRAE, C2VN, Aix-Marseille University, 13005 Marseille, France"},{"name":"Department of Internal Medicine, Timone University Hospital, 13005 Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2938-2201","authenticated-orcid":false,"given":"Anne-Laure","family":"Couderc","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, South University Hospital, 13005 Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Tichadou","sequence":"additional","affiliation":[{"name":"Hematology and Cellular Therapy Department, Conception University Hospital, 13005 Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Roche","sequence":"additional","affiliation":[{"name":"Hematology and Cellular Therapy Department, Conception University Hospital, 13005 Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laure","family":"Farnault","sequence":"additional","affiliation":[{"name":"Hematology and Cellular Therapy Department, Conception University Hospital, 13005 Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Colle","sequence":"additional","affiliation":[{"name":"INSERM, INRAE, C2VN, Aix-Marseille University, 13005 Marseille, France"},{"name":"Hematology and Cellular Therapy Department, Conception University Hospital, 13005 Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u2019houcine","family":"Ouafik","sequence":"additional","affiliation":[{"name":"CNRS, INP, Institute of Neurophysiopathol, Aix-Marseille Universit\u00e9, 13005 Marseille, France"},{"name":"APHM, CHU Nord, Service d\u2019Onco-Biologie, Aix-Marseille Universit\u00e9, 13005 Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Morange","sequence":"additional","affiliation":[{"name":"INSERM, INRAE, C2VN, Aix-Marseille University, 13005 Marseille, France"},{"name":"Hematology Laboratory, Timone University Hospital, 13005 Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9gis","family":"Costello","sequence":"additional","affiliation":[{"name":"INSERM, INRAE, C2VN, Aix-Marseille University, 13005 Marseille, France"},{"name":"Hematology and Cellular Therapy Department, Conception University Hospital, 13005 Marseille, France"},{"name":"TAGC, INSERM, UMR1090, Aix-Marseille University, 13005 Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffroy","family":"Venton","sequence":"additional","affiliation":[{"name":"INSERM, INRAE, C2VN, Aix-Marseille University, 13005 Marseille, France"},{"name":"Hematology and Cellular Therapy Department, Conception University Hospital, 13005 Marseille, France"},{"name":"TAGC, INSERM, UMR1090, Aix-Marseille University, 13005 Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and Personalized Prognosis in Myeloproliferative Neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.jmoldx.2016.05.006","article-title":"Rapid Molecular Profiling of Myeloproliferative Neoplasms Using Targeted Exon Resequencing of 86 Genes Involved in JAK-STAT Signaling and Epigenetic Regulation","volume":"18","author":"Magor","year":"2016","journal-title":"J. Mol. Diagn."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jmoldx.2018.07.002","article-title":"Clinical Significance of DNA Variants in Chronic Myeloid Neoplasms: A Report of the Association for Molecular Pathology","volume":"20","author":"McClure","year":"2018","journal-title":"J. Mol. Diagn."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"12367","DOI":"10.2147\/OTT.S287944","article-title":"Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data","volume":"13","author":"Loscocco","year":"2020","journal-title":"OncoTargets Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.pathol.2021.01.003","article-title":"Myeloid somatic mutation panel testing in myeloproliferative neoplasms","volume":"53","author":"Ross","year":"2021","journal-title":"Pathology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/bloodadvances.2016000208","article-title":"Targeted deep sequencing in primary myelofibrosis","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of Mutation Order on Myeloproliferative Neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","article-title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1182\/bloodadvances.2018015875","article-title":"Targeted next-generation sequencing in blast phase myeloproliferative neoplasms","volume":"2","author":"Lasho","year":"2018","journal-title":"Blood Adv."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/leu.2010.113","article-title":"IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/leu.2014.76","article-title":"The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: An international study of 797 patients","volume":"28","author":"Guglielmelli","year":"2014","journal-title":"Leukemia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/leu.2014.57","article-title":"CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: An international study of 570 patients","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/bjh.15010","article-title":"Screening for ASXL1 and SRSF2 mutations is imperative for treatment decision-making in otherwise low or intermediate-1 risk patients with myelofibrosis","volume":"183","author":"Tefferi","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.bbmt.2017.03.034","article-title":"Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation","volume":"23","author":"Panagiota","year":"2017","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/leu.2017.318","article-title":"Prognostic significance of ASXL1 mutation types and allele burden in myelofibrosis","volume":"32","author":"Tefferi","year":"2017","journal-title":"Leukemia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1182\/blood-2011-06-363424","article-title":"EZH2 mutational status predicts poor survival in myelofibrosis","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20151136","article-title":"Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis","volume":"213","author":"Shimizu","year":"2016","journal-title":"J. Exp. Med."},{"key":"ref_20","first-page":"20","article-title":"Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2\/MPL\/CALR) and SF3B1","volume":"34","author":"Ok","year":"2020","journal-title":"Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1182\/blood-2011-11-390252","article-title":"Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome","volume":"119","author":"Zhang","year":"2012","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/ajh.24978","article-title":"Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1095 patients","volume":"93","author":"Tefferi","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/s41375-020-0979-6","article-title":"Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide","volume":"35","author":"Chowdhury","year":"2020","journal-title":"Leukemia"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/leu.2017.139","article-title":"The role of LNK\/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders","volume":"31","author":"Maslah","year":"2017","journal-title":"Leukemia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"E356","DOI":"10.1002\/ajh.24437","article-title":"Germline transmission of LNKE208Q variant in a family with myeloproliferative neoplasms","volume":"91","author":"Loscocco","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1182\/blood-2016-04-711150","article-title":"LNK mutations in familial myeloproliferative neoplasms","volume":"128","author":"Rumi","year":"2016","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature08240","article-title":"Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms","volume":"460","author":"Sanada","year":"2009","journal-title":"Nature"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1182\/bloodadvances.2020002175","article-title":"RAS\/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features","volume":"4","author":"Coltro","year":"2020","journal-title":"Blood Adv."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1158\/1078-0432.CCR-07-1005","article-title":"Targeting Ras in Myeloid Leukemias","volume":"14","author":"Braun","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1084\/jem.20120521","article-title":"MPN patients harbor recurrent truncating mutations in transcription factor NF-E2","volume":"210","author":"Jutzi","year":"2013","journal-title":"J. Exp. Med."},{"key":"ref_32","first-page":"E23","article-title":"Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms","volume":"95","author":"Guglielmelli","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1182\/blood-2018-05-850339","article-title":"PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells","volume":"132","author":"Kahn","year":"2018","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1007\/s00277-018-3402-x","article-title":"The co-occurrence of driver mutations in chronic myeloproliferative neoplasms","volume":"97","author":"Boddu","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.3109\/10428194.2015.1015124","article-title":"Co-existence of JAK2 V617F and CALR mutations in primary myelofibrosis","volume":"56","author":"Zamora","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/bjh.15954","article-title":"Next generation sequencing redefines a triple negative essential thombocythaemia as double-positive with rare mutations on JAK2 V617 and MPL W515 hotspots","volume":"186","author":"Beucher","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"E264","DOI":"10.1002\/ajh.25580","article-title":"Diagnostic and prognostic contribution of targeted NGS in patients with triple-negative myeloproliferative neoplasms","volume":"94","author":"Acha","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/ajh.25230","article-title":"Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management","volume":"93","author":"Tefferi","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2006-10-054940","article-title":"The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera","volume":"110","author":"Dupont","year":"2007","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/bjh.13047","article-title":"The role of serum erythropoietin level and JAK2 V617F allele burden in the diagnosis of polycythaemia vera","volume":"167","author":"Ancochea","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.5858\/arpa.2013-0018-OA","article-title":"Megakaryocytic Morphology and Clinical Parameters in Essential Thrombocythemia, Polycythemia Vera, and Primary Myelofibrosis With and Without JAK2V617F","volume":"138","author":"Vytrva","year":"2014","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1182\/blood-2009-12-257501","article-title":"Failure of the Ipsogen MutaScreen kit to detect the JAK2 617V>F mutation in samples with additional rare exon 14 mutations: Implications for clinical testing and report of a novel 618C>F mutation in addition to 617V>F","volume":"115","author":"Warshawsky","year":"2010","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/bjh.14126","article-title":"Apparent \u2018JAK2-negative\u2019 polycythaemia vera due to compound mutations in exon 14","volume":"178","author":"Tiong","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.3324\/haematol.2016.144063","article-title":"Gene panel sequencing improves the diagnostic work-up of patients with idiopathic erythrocytosis and identifies new mutations","volume":"101","author":"Camps","year":"2016","journal-title":"Haematologica"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1182\/bloodadvances.2018020222","article-title":"Clinical consequences of clonal hematopoiesis of indeterminate potential","volume":"2","author":"Steensma","year":"2018","journal-title":"Blood Adv."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.exphem.2009.07.005","article-title":"JAK2V617F allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis","volume":"37","author":"Hussein","year":"2009","journal-title":"Exp. Hematol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"E121","DOI":"10.1002\/ajh.23743","article-title":"Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients","volume":"89","author":"Tefferi","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","article-title":"GIPSS: Genetically inspired prognostic scoring system for primary myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3324\/haematol.2011.047811","article-title":"European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis","volume":"97","author":"Buhr","year":"2011","journal-title":"Haematologica"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2007-05-091850","article-title":"Bone marrow pathology in essential thrombocythemia: Interobserver reliability and utility for identifying disease subtypes","volume":"111","author":"Wilkins","year":"2008","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/bjh.16380","article-title":"Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera","volume":"189","author":"Tefferi","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood-2017-05-783225","article-title":"Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"130","author":"Newberry","year":"2017","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood.2019000943","article-title":"Leukemia secondary to myeloproliferative neoplasms","volume":"136","author":"Dunbar","year":"2020","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","article-title":"MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis","volume":"36","author":"Tefferi","year":"2018","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"E107","DOI":"10.1002\/ajh.25407","article-title":"Changing incidence of myeloproliferative neoplasms in Australia, 2003\u20132014","volume":"94","author":"Baade","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/bloodadvances.2019001084","article-title":"Survival following allogeneic transplant in patients with myelofibrosis","volume":"4","author":"Gowin","year":"2020","journal-title":"Blood Adv."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/gcc.21960","article-title":"Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms","volume":"51","author":"Brecqueville","year":"2012","journal-title":"Genes. Chromosomes Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/leu.2011.320","article-title":"SF3B1 mutations in primary myelofibrosis: Clinical, histopathology and genetic correlates among 155 patients","volume":"26","author":"Lasho","year":"2012","journal-title":"Leukemia"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1182\/blood-2012-05-429696","article-title":"SRSF2 mutations in primary myelofibrosis: Significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival","volume":"120","author":"Lasho","year":"2012","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1182\/blood-2008-12-194548","article-title":"Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms","volume":"113","author":"Grand","year":"2009","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2011.58","article-title":"Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms","volume":"25","author":"Pardanani","year":"2011","journal-title":"Leukemia"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/ajh.22216","article-title":"TP53 mutations and polymorphisms in primary myelofibrosis","volume":"87","author":"Raza","year":"2011","journal-title":"Am. J. Hematol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/ajh.24973","article-title":"Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms","volume":"93","author":"Venton","year":"2017","journal-title":"Am. J. Hematol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/1\/105\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:52:10Z","timestamp":1760147530000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/1\/105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,27]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["cells12010105"],"URL":"https:\/\/doi.org\/10.3390\/cells12010105","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,27]]}}}